IMDX

MKT CAP:$102M

Insight Molecular Diagnostics Inc.

Market Cap

$102M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$3.45-$3.71 (-51.82%)

Apr 23, 2026

Company Details

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a mol...

CEO

Joshua Riggs

IPO Date

Dec 30, 2015

Website

imdxinc.com

Key Metrics TTM

Revenue

$4M

+115.6% YoY

Net Income

-$50M

EPS (Diluted)

-$1.65

Free Cash Flow

-$25M

Revenue / Share

$0.13

Gross Margin

4.7%

Operating Margin

-754.1%

Net Margin

-1238.5%

FCF Margin

-625.6%

P/S

25.3x

P/E

—

Earnings Reports

Q1 2026

May 11, 2026

PENDING

FY 2025

Mar 26, 2026

$4MEPS -$1.65

Q4 2025

Mar 26, 2026

$1M-23.4%EPS -$0.75

Q3 2025

Nov 10, 2025

$260.0K+126.1%EPS -$0.34

Q2 2025

Aug 11, 2025

$518.0K+398.1%EPS -$0.30

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 21	$2M	-$394.0K	-$14M
Q3 21	$984.0K	-$866.0K	-$14M
Q4 21	$4M	$1M	-$36M
Q4 22	$274.0K	-$4.0K	-$12M
Q1 23	$297.0K	$10.0K	$6M
Q2 23	$463.0K	$272.0K	-$8M
Q3 23	$429.0K	$248.0K	-$7M
Q4 23	$314.0K	-$95.0K	-$16M
Q1 24	$176.0K	$45.0K	-$9M
Q2 24	$104.0K	$50.0K	-$5M
Q3 24	$115.0K	$50.0K	-$14M
Q4 24	$1M	$595.0K	-$34M
Q1 25	$2M	$1M	-$7M
Q2 25	$518.0K	$350.0K	-$10M
Q3 25	$260.0K	$139.0K	-$11M
Q4 25	$1M	-$2M	-$3M

Valuation

Quarter	P/S	P/E
Q2 21	127.9x	—
Q3 21	77.0x	—
Q4 21	26.9x	—
Q4 22	6.6x	—
Q1 23	10.0x	—
Q2 23	8.2x	—
Q3 23	17.6x	—
Q4 23	18.6x	—
Q1 24	27.8x	—
Q2 24	39.5x	—
Q3 24	69.9x	—
Q4 24	22.6x	—
Q1 25	25.5x	—
Q2 25	22.7x	—
Q3 25	23.5x	—
Q4 25	52.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 21	-$8M	-$9M
Q3 21	-$11M	-$11M
Q4 21	-$7M	-$7M
Q4 22	-$10M	-$10M
Q1 23	-$8M	-$8M
Q2 23	-$7M	-$7M
Q3 23	-$2M	-$2M
Q4 23	-$5M	-$5M
Q1 24	-$4M	-$4M
Q2 24	-$6M	-$6M
Q3 24	-$6M	-$5M
Q4 24	-$5M	-$6M
Q1 25	-$6M	-$6M
Q2 25	-$6M	-$7M
Q3 25	-$5M	-$6M
Q4 25	-$6M	-$7M

Capital Expenditures

Quarter	CapEx
Q2 21	$610.0K
Q3 21	$394.0K
Q4 21	$401.0K
Q4 22	$802.0K
Q1 23	$0
Q2 23	$0
Q3 23	$17.0K
Q4 23	$264.0K
Q1 24	$24.0K
Q2 24	$191.0K
Q3 24	$215.0K
Q4 24	$214.0K
Q1 25	$307.0K
Q2 25	$349.0K
Q3 25	$1M
Q4 25	$1M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 21	+1319.6%	+75.0%
Q3 21	+77.3%	+114.6%
Q4 21	+613.5%	+480.0%
Q4 22	-75.6%	-4.5%
Q1 23	-85.4%	-135.6%
Q2 23	-52.9%	-40.0%
Q3 23	-88.0%	-82.3%
Q4 23	+14.6%	+38.3%
Q1 24	-40.7%	+270.1%
Q2 24	-77.5%	-45.9%
Q3 24	-73.2%	+96.3%
Q4 24	+373.2%	+112.9%
Q1 25	+1114.8%	-5.4%
Q2 25	+398.1%	+118.8%
Q3 25	+126.1%	-17.0%
Q4 25	-23.4%	-88.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 21	$2M	98.3%
Q3 21	$2M	188.0%
Q4 21	$2M	47.5%
Q4 22	$3M	955.8%
Q1 23	$834.0K	280.8%
Q2 23	$834.0K	180.1%
Q3 23	$608.0K	141.7%
Q4 23	$611.0K	194.6%
Q1 24	$464.0K	263.6%
Q2 24	$202.0K	194.2%
Q3 24	$354.0K	307.8%
Q4 24	$549.0K	36.9%
Q1 25	$487.0K	22.8%
Q2 25	$504.0K	97.3%
Q3 25	$0	0.0%
Q4 25	$721.0K	63.3%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q2 21	$3M	$8M	$397.0K
Q3 21	$3M	$8M	$376.0K
Q4 21	$5M	$4M	$3M
Q4 22	$1M	$4M	$334.0K
Q1 23	$2M	$4M	$44.0K
Q2 23	$2M	$4M	$81.0K
Q3 23	$2M	$3M	$77.0K
Q4 23	$3M	$2M	$582.0K
Q1 24	$2M	$3M	$84.0K
Q2 24	$2M	$2M	$853.0K
Q3 24	$3M	$3M	$1M
Q4 24	$2M	$3M	$238.0K
Q1 25	$3M	$3M	$1M
Q2 25	$3M	$3M	$1M
Q3 25	$4M	$3M	$1M
Q4 25	$6M	$2M	$2M

Revenue Segments

Quarter	Pharma Services	Laboratory Services
Q1 25	$2M	—
Q2 25	—	$494.0K

Revenue by Geography

Quarter	United States	Europe
Q1 25	$2M	—
Q2 25	$494.0K	$24.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$20M	$574.0K	$21M
Q2 22	$45M	$579.0K	$45M
Q3 22	$32M	$419.0K	$32M
Q4 22	$20M	$433.0K	$20M
Q1 23	$12M	$553.0K	$12M
Q2 23	$17M	$530.0K	$18M
Q3 23	$14M	$441.0K	$14M
Q4 23	$9M	$0	$9M
Q1 24	$6M	$0	$6M
Q2 24	$9M	$0	$9M
Q3 24	$3M	$0	$3M
Q4 24	$9M	$0	$9M
Q1 25	$31M	$0	$31M
Q2 25	$24M	$0	$24M
Q3 25	$19M	$0	$19M
Q4 25	$12M	$0	$12M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 21	4M	+9.3%	+36.3%
Q3 21	5M	+1.9%	+36.0%
Q4 21	5M	+0.8%	+36.9%
Q4 22	6M	+28.8%	+44.6%
Q1 23	6M	+0.4%	+32.9%
Q2 23	8M	+35.7%	+76.9%
Q3 23	8M	+2.1%	+79.1%
Q4 23	8M	+0.1%	+39.2%
Q1 24	8M	+0.0%	+38.6%
Q2 24	13M	+55.7%	+59.1%
Q3 24	14M	+6.6%	+66.1%
Q4 24	17M	+26.7%	+110.4%
Q1 25	26M	+47.8%	+210.9%
Q2 25	32M	+24.6%	+148.8%
Q3 25	32M	+0.0%	+133.6%
Q4 25	30M	-4.9%	+75.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 21	$39.8K	51
Q3 21	$19.3K	51
Q4 21	$32.6K	110
Q4 22	$3.6K	76
Q1 23	$3.9K	76
Q2 23	$6.1K	76
Q3 23	$5.6K	76
Q4 23	$6.8K	46
Q1 24	$3.8K	46
Q2 24	$2.3K	46
Q3 24	$2.5K	46
Q4 24	$30.3K	49
Q1 25	$43.6K	49
Q2 25	$10.6K	49
Q3 25	$5.3K	49
Q4 25	$19.6K	58

Revenue / Employee